Johnson & Johnson
JNJNYSE
$265.04
Last price · USD
- Market cap
- $643.9B
- P/E
- 24.0x
- EV / EBITDA
- 16.4x
- P/S
- 6.8x
- FCF yield
- 3.1%
- Div. yield
- 1.92%
Multiples use last price and FY2025 annual figures. Market cap estimated from diluted shares.
Revenue
$94.19B
+6.0%
4Y CAGR +4.6%
Gross profit
$63.94B
+4.2%
4Y CAGR +3.7%
Operating income
$25.60B
+15.6%
4Y CAGR +5.1%
Net income
$26.80B
+90.6%
4Y CAGR +6.4%
EPS (diluted)
$11.03
+90.5%
4Y CAGR +9.0%
Free cash flow
$19.70B
-0.7%
4Y CAGR -0.1%
Revenue & net income
Fiscal 2021–2025 · USD
RevenueNet income
Valuation
At $265.04 · FY2025 fundamentals
- Market cap
- $643.9B
- Enterprise value
- $672.1B
- P/E
- 24.0x
- P/S
- 6.8x
- P/B
- 7.9x
- EV / EBITDA
- 16.4x
- EV / Sales
- 7.1x
- Earnings yield
- 4.2%
- FCF yield
- 3.1%
- Shareholder yield
- 2.8%
Profitability
Margins as a share of revenue
| Metric | Latest | 4Y ago | Trend |
|---|---|---|---|
| Gross margin | 67.9%-2.4pp | 70.3% | |
| Operating margin | 27.2%+0.6pp | 26.6% | |
| EBITDA margin | 43.6%+9.6pp | 34.0% | |
| Net margin | 28.5%+1.9pp | 26.5% | |
| FCF margin | 20.9%-4.2pp | 25.1% |
Returns & financial health
FY2025 with 4-year trend
| Metric | Latest | 4Y ago | Trend |
|---|---|---|---|
| Return on equity | 32.9% | 28.2% | |
| Return on invested capital | 19.2% | 20.8% | |
| Return on assets | 13.5% | 11.5% | |
| Debt / equity | 0.59x | 0.46x | |
| Net debt / EBITDA | 0.69x | 0.72x | |
| Current ratio | 1.03x | 1.35x |
Cash & equivalents
$19.71B
Total debt
$47.93B
Capital allocation
How JNJ used its cash in FY2025
- Operating cash flow
- $24.53B
- Capital expenditure
- $4.83B
- Dividends paid
- $12.38B
- Share repurchases
- $5.95B
- Stock-based compensation
- $1.35B
- Diluted shares
- 2.43B
- Share count change (4Y)
- -9.1%
Analyst estimates
Consensus for upcoming fiscal years
| Fiscal year | Revenue | Growth | EPS | Growth |
|---|---|---|---|---|
| FY2025 actual | $94.19B | $11.03 | ||
| FY2026E11 analysts | $101.2B | +7.5% | $11.11 | +0.7% |
| FY2027E12 analysts | $107.9B | +6.6% | $11.60 | +4.4% |
| FY2028E5 analysts | $116.7B | +8.1% | $13.97 | +20.5% |
About Johnson & Johnson
Healthcare · Drug Manufacturers - General
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.
jnj.com- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Joaquin Duato
- Employees
- 141,700
- Headquarters
- New Brunswick, NJ, US
- IPO date
- 1962-01-02
Johnson & Johnson (JNJ) — frequently asked questions
Answered from the company's SEC filings
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments.
Explore the full income statement, balance sheet and cash flow statement. Not investment advice.